Revolution Medicines Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
RVMD$200.15+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $543,064 | $696,148 |
| Marketable securities | 1,746,235 | 1,156,807 |
| Accounts receivable | — | 1,254 |
| Prepaid expenses and other current assets | 38,333 | 25,072 |
| Total current assets | 2,327,632 | 1,879,281 |
| Property and equipment, net | 24,289 | 22,865 |
| Operating lease right-of-use asset | 117,534 | 77,149 |
| Intangible assets, net | 56,670 | 57,739 |
| Goodwill | 14,608 | 14,608 |
| Restricted cash | 3,698 | 3,031 |
| Other noncurrent assets | 13,870 | 7,032 |
| Total assets | $2,558,301 | $2,061,705 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: | ||
| Accounts payable | $54,427 | $61,788 |
| Accrued expenses and other current liabilities | 96,615 | 74,694 |
| Operating lease liability, current | 12,872 | 7,369 |
| Total current liabilities | 163,914 | 143,851 |
| Deferred tax liability | 2,353 | 3,115 |
| Operating lease liability, noncurrent | 122,971 | 80,575 |
| Warrant liability | 3,189 | 6,512 |
| Other noncurrent liabilities | 670 | 1,458 |
| Total liabilities | 293,097 | 235,511 |
| Commitments and contingencies (Note 8) | ||
| Stockholdersʼ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; none issued and outstanding at December 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 185,896,625 and 170,234,594 shares issued as of December 31, 2024 and December 31, 2023; 185,896,625 and 164,674,594 shares outstanding as of December 31, 2024 and December 31, 2023, respectively | 18 | 16 |
| Additional paid-in capital | 4,001,666 | 2,963,342 |
| Accumulated other comprehensive income | 1,321 | 544 |
| Accumulated deficit | (1,737,801) | (1,137,708) |
| Total stockholdersʼ equity | 2,265,204 | 1,826,194 |
| Total liabilities and stockholdersʼ equity | $2,558,301 | $2,061,705 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.